- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04744116
Tilsætning af navlestrengsblod-afledte mesenkymale stromaceller til Ruxolitinib til behandling af steroid-refraktær akut graft versus værtssygdom
En randomiseret kontrolleret pilotundersøgelse af to doser navlestrengsblod-afledte mesenkymale stromaceller kombineret med ruxolitinib versus ruxolitinib alene til behandling af steroid-refraktær akut graft versus værtssygdom
This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid therapy (steroid-refractory). Ruxolitinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. cb-MSCs are a type of tissue helper cell that can be removed from donated umbilical cord blood tissue and grown into many different cell types that can be used to treat cancer and other disease, such as graft versus host disease. This trial aims to learn if adding cb-MSCs to ruxolitinib may help control steroid-refractory acute graft versus host disease.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To estimate between-arm differences (Arm 3 versus [vs] Arm 1, and Arm 2 vs Arm 1) for each of the 28-day co-primary outcome probabilities.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM 1: Patients receive ruxolitinib orally (PO) twice daily (BID) for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued.
ARM 2: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs intravenously (IV) for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
ARM 3: Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses.
After completion of study treatment, patients are followed up on day 28 and then for up to 6 months.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Tidlig fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Partow Kebriaei, MD
- Telefonnummer: 713-745-0663
- E-mail: pkebriae@mdanderson.org
Studiesteder
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- Rekruttering
- M D Anderson Cancer Center
-
Kontakt:
- Partow Kebriaei, MD
- Telefonnummer: 713-745-0663
- E-mail: pkebriae@mdanderson.org
-
Ledende efterforsker:
- Partow Kebriaei, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Participants between the ages of 12 years and 80 years (inclusive).
- Steroid refractory grades II-IV acute GVHD of the Lower GI tract or Liver (including those developing these manifestations after previous acute GVHD of skin) secondary to allogeneic HCT or donor lymphocyte infusion. (Grading, see Appendix I) GVHD with: No improvement after treatment with methylprednisolone at ≥ 2.0 mg/kg/day or equivalent for minimum 7 days, or progressive symptoms after minimum 3 days, or a flare in acute GVHD while on systemic steroids. Participants must have had a biopsy that suggests GVHD; a repeat biopsy to enroll on the study is not necessary.
- Karnofsky/Lansky Performance score of at least 30 at the time of study entry.
- Participants who are women of childbearing potential, must be non-pregnant, not breast-feeding, and use adequate contraception. Male patients must use adequate contraception
- Participants (or legal representative where appropriate) must be capable of providing written informed consent, and assent if indicated.
Exclusion Criteria:
- De novo chronic GVHD
- Isolated acute GVHD of skin
- Secondary systemic therapy for acute GVHD ruxolitinib greater than 96 hours before initiation of therapy.
- Primary treatment with agents other than alpha-1 antitrypsin (AAT) glucocorticoids and ruxolitinib.
- Participants with uncontrolled infections will be excluded. Infections are considered controlled if appropriate therapy has been instituted and, at the time of enrollment, no signs of progression are present. Progression of infection is defined as hemodynamic instability attributable to sepsis, new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection.
- Adult and pediatric patients with cognitive impairments and/or any serious unstable pre-existing medical condition or psychiatric disorder that can interfere with safety or with obtaining informed consent or compliance with study procedures.
- Participants with significant supplemental oxygen requirement defined as >6 L oxygen by nasal cannula.
- Participants with known allergy to bovine or porcine products.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Arm 1 (ruxolitinib)
Patients receive ruxolitinib PO BID for at least 3 days and may consider tapering after 6 months of therapy if response occurs and therapeutic corticosteroid doses have been discontinued. |
Given PO
Andre navne:
|
|
Eksperimentel: Arm 2 (ruxolitinib, lower dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses. |
Given PO
Andre navne:
Given ds-MSCs IV
Andre navne:
|
|
Eksperimentel: Arm 3 (ruxolitinib, higher dose ds-MSCs)
Patients receive ruxolitinib PO BID as in Arm 1. Patients also receive higher dose of cb-MSCs IV for up to 60 minutes twice weekly (at least 3 days apart) over 4 consecutive weeks for 8 total doses. |
Given PO
Andre navne:
Given ds-MSCs IV
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Død af enhver årsag
Tidsramme: Inden for 28 dage fra start af aktiv undersøgelsesbehandling
|
Inden for 28 dage fra start af aktiv undersøgelsesbehandling
|
|
|
Forekomst af uønskede hændelser
Tidsramme: Inden for 28 dage fra start af aktiv undersøgelsesbehandling
|
Inden for 28 dage fra start af aktiv undersøgelsesbehandling
|
|
|
Response
Tidsramme: At day 28 from start of therapy on study
|
Will compare the patient's 28-day graft versus host disease (GVHD) status to the patient's baseline GVHD status when steroid refractory acute GVHD was diagnosed. |
At day 28 from start of therapy on study
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Forekomst af fuldstændig respons for hvert organ
Tidsramme: Op til 6 måneder
|
Op til 6 måneder
|
|
|
Forekomst af meget god delvis respons for hvert organ
Tidsramme: Op til 6 måneder
|
Op til 6 måneder
|
|
|
Forekomst af delvis respons for hvert organ
Tidsramme: Op til 6 måneder
|
Op til 6 måneder
|
|
|
Holdbarhed af organrespons
Tidsramme: Op til 6 måneder
|
Op til 6 måneder
|
|
|
Kumulativ forekomst af ikke-tilbagefaldsdødelighed (NRM)
Tidsramme: 6 måneder efter behandling
|
6 måneder efter behandling
|
|
|
Kumulativ forekomst af tilbagefald/progression af den primære sygdom
Tidsramme: Ved 6 måneder
|
Ved 6 måneder
|
|
|
Samlet overlevelse
Tidsramme: Fra indskrivning til død uanset årsag, vurderet til 6 måneder
|
Fra indskrivning til død uanset årsag, vurderet til 6 måneder
|
|
|
Sygdomsfri overlevelse
Tidsramme: Fra indskrivning til død af enhver årsag eller tilbagefald/progression af den primære sygdom, vurderet efter 6 måneder
|
Fra indskrivning til død af enhver årsag eller tilbagefald/progression af den primære sygdom, vurderet efter 6 måneder
|
|
|
Forekomst af enhver grad af cytokinfrigivelse
Tidsramme: Op til 28 dage efter afslutning af sidste MSC-infusionsundersøgelseslægemiddel
|
Op til 28 dage efter afslutning af sidste MSC-infusionsundersøgelseslægemiddel
|
|
|
Forekomst af enhver infusionstoksicitet
Tidsramme: Inden for 24 timer efter hver navlestrengsblod-MSC-infusion
|
Inden for 24 timer efter hver navlestrengsblod-MSC-infusion
|
|
|
Graft versus host disease status
Tidsramme: At days 7, 14, 21 and 28 post treatment
|
Will assess complete response (CR), very good partial response (VGPR), partial response (PR), stable disease (SD), and progressive disease (PD). |
At days 7, 14, 21 and 28 post treatment
|
|
Proportion of response
Tidsramme: At days 7, 14, 21 and 28 post treatment
|
Will assess proportion of patients with CR, PR, VGPR, and no-response (NR). The event NR is defined as stable disease, mixed response, disease progression, OR initiation of additional systemic (second-line) GVHD therapies. |
At days 7, 14, 21 and 28 post treatment
|
|
Time to complete response
Tidsramme: Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Time to very good partial response
Tidsramme: Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Time to partial response
Tidsramme: Up to 6 months
|
Will be estimated by the method of Kaplan and Meier. |
Up to 6 months
|
|
Graft versus host disease-free survival
Tidsramme: At 6 months
|
Patients alive, free of active acute or chronic GVHD, and without other systemic agents (or escalation of steroids to >= 2.5 mg/kg/day of prednisone [or methylprednisolone equivalent of 2 mg/kg/day]) added for treatment of GVHD will be considered successes for this endpoint |
At 6 months
|
|
Incidence of chronic graft versus host disease
Tidsramme: At 6 months after first mesenchymal stromal cells (MSC) infusion
|
Chronic GVHD is defined per National Institutes of Health Consensus Criteria. Diagnosis of chronic GVHD of any severity (mild, moderate, or severe) is considered an event for this endpoint. Organ involvement and maximum severity will also be described at six months. |
At 6 months after first mesenchymal stromal cells (MSC) infusion
|
|
Incidence of systemic infections
Tidsramme: 28 days after last study drug
|
The incidence of grade 2 to 3 systemic infections occurring from study treatment until 28 days after last study drug will be described using standard Common Terminology Criteria for Adverse Events (CTCAE) criteria. Infections will be recorded by site of disease, date of onset, and severity. |
28 days after last study drug
|
|
Incidence of toxicities
Tidsramme: Up to 28 days after completing last MSC infusion study drug
|
The incidence of grade 3-5 treatment-emergent adverse events (per CTCAE version 5.0) that occur through 28 days after completing last MSC infusion study drug will be described. |
Up to 28 days after completing last MSC infusion study drug
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Cytokine biomarker analysis (optional)
Tidsramme: Up to 6 months
|
Will use cytokine biomarker assays to predict response to therapy. |
Up to 6 months
|
|
Fecal samples analysis (optional)
Tidsramme: Up to 6 months
|
Will use fecal samples to assess microbiome and potential predictor for response to therapy. |
Up to 6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Ledende efterforsker: Partow Kebriaei, MD, M.D. Anderson Cancer Center
Publikationer og nyttige links
Hjælpsomme links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 2019-1122
- 2019-1122 (Anden identifikator: M D Anderson Cancer Center)
- NCI-2020-13889 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- P01CA148600 (U.S. NIH-bevilling/kontrakt)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .